Kornimate/medical-research-clean huggingface dataset:
surgical mesh in radical cystectomy to prevent parastomal hernias

Conditions: Bladder Cancer; Hernia; Ileal Conduit

Summary: radical cystectomy with ileal conduit urinary diversion serves as a foundational curative treatment strategy for selected patients afflicted with urothelial carcinoma of the bladder. parastomal hernia after this procedure is an underestimated and undertreated clinical entity, which heavily impairs patients' quality of life due to symptoms of pain, leakage, application or skin problems. there is little evidence about prophylactic mesh placement for parastomal hernia prevention. in this study we examine the use of meshes during radical cystectomy and compare them with a control group.

radical cystectomy with ileal conduit diversion is a procedure possible with complications. a primary stoma-related complication is the parastomal hernia (ph), which presents significant challenges to both the medical community and the patient. ph is classically defined as the protrusion of abdominal contents via the abdominal wall, especially in the direct vicinity of a stoma, whether it be a colostomy, ileostomy, or ileal conduit stoma. the incidence of ph post ileal conduit urinary diversion is especially concerning, with reports estimating its occurrence at around 17%. this data only emphasizes the need to reevaluate and optimize surgical treatments for ph, particularly as, in many cases, management strategies are extrapolated from experiences with colostomies or ileostomies. notably, phs are often described after these procedures rather than rc with ileal conduit urinary diversion. further complicating the issue is the fact that estimates suggest around 30% of patients develop a ph within 12 months post any type of stoma site surgery. for those undergoing ileal conduit urinary diversion specifically, recurrence rates following ph repair can be alarmingly high, with figures as steep as 69% within a year.

Eligibility criteria:
inclusion criteria: * muscle-invasive or high-risk non-muscle-invasive bladder cancer patients exclusion criteria: * different than surgical therapy

Keywords: radical cystectomy ileal conduit parastomal hernia mesh
prospective study to quantify the change in weight at a pneumonia

Conditions: Hospitalisation for Pneumonia

Summary: this study is based on the change in weight of hospitalized patients knowing that the diagnosis of malnutrition based on the presence of at least one clinical or laboratory test which anthropometric measures (evaluation of diagnostic protein energy malnutrition in hospitalized adults anaes , guidelines department, september 2003; has strategy supported in cases of wasting energy and protein in the elderly april 2007). the goal of this study is to find the correlation between hospitalization and weight loss, significant risk factors for malnutrition in a situation of community-acquired pneumonia infection.


Eligibility criteria:
inclusion criteria: * cough * fever \> 38.5 ° c * tachycardia \> 100 / min * chest pain lateralized * absence of infection high respiratory tract * global impression of severity * fireplace auscultatory signs (rattle crackling) exclusion criteria: * pregnant women * dialysis patients * any patient with home oxygen or under a home care for bpco stage 3 or 4 * patients transferred from intensive care * patients with severe sepsis and requiring a "filler" * enteral or parenteral nutrition
effects of soy isoflavone on bone health among saudi female students imam abdulrahman bin faisal university.

Conditions: Soy Isoflavone Effect; Bone Density, Low; Bone Density Increased

Summary: low bone mineral density (bmd) has recently increased among young women. soy isoflavone as a food supplement, has been found to have potent effect on bone health in postmenopausal women. however, the effect of soy isoflavone on pre-menopausal is not well understood. this research is done to examine the effect of soy isoflavones on bmd among young university female students.


Eligibility criteria:
inclusion criteria: * female * university students * aged between 18-25 years exclusion criteria: * study participants who use medications and suffer from diseases that may interfere or effect on bmd, use calcium and vitamin d supplements and who suffer from glucose 6 phosphate deficiency (g6pd) were excluded from the study.
characteristics of non diabetic hyperglycemic inpatients

Conditions: Diabetes Mellitus

Summary: retrospective nested non-matched case control study comparing patients by glycemic status

this retrospective nested non-matched case control study compared patients directly admitted to the general medicine wards, not transferred from icu with * hyperglycemia on admission but no previous diagnosis of diabetes * diabetic hyperglycemic patients * non hyperglycemic non diabetic patients from the same nested population. the investigators' hypothesis is that the clinical characteristics and endpoints of the non diabetic hyperglycemics should be similar to the diabetic population and different from the non diabetic non hyperglycemic population.

Eligibility criteria:
inclusion criteria: * admitted to john h. stroger jr. hospital * admitted to internal medicine service from march-april 2006 and in october 2007 exclusion criteria: * transfer from any intensive care unit (medical or surgical)

Keywords: diabetes inpatient hospital hyperglycemia
sitagliptin (dpp-4 inhibitor) and nph insulin in patients with t2d

Conditions: Type 2 Diabetes Mellitus

Summary: to compare the short and long term effects of inhibitor of the dpp-iv enzyme, sitagliptin , with bedtime nph insulin in patients with t2d inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile.

glucose control is fundamental in the treatment of type 2 diabetes (dm2). studies suggest that drugs that boost levels of glucagon-like peptide (glp-1) improve glycemic control and have long-term beneficial effect on the function of pancreatic beta cells. objective: to compare the short and long term effects of sitagliptin (which inhibits the dpp-iv enzyme, increasing the levels of glp-1) with bedtime nph insulin in patients with t2d inadequately controlled with sulphonylurea plus biguanide. effects on beta cell function and on metabolic profile were analyzed. methods: 40 patients with dm2, hba1c between 6.6 to 10%, in use of metformin and glibenclamide will be randomized to the addition of sitagliptin (sitagliptin group) or of bedtime nph insulin (nph group). measurements of hba1c, metabolic and hormonal profile at fasting and post-meal (every 30 minutes for 4 hours) will be evaluated before and after 6 months (short term) and 12 months (long term) of adding sitagliptin or nph insulin.

Eligibility criteria:
inclusion criteria * outpatients with t2d inadequately controlled with metformin plus glyburide * hba1c levels between 6.6 and 10% * body mass index \< 35 kg/m2 exclusion criteria * heart failure * respiratory failure * uncontrolled hypertension * impaired hepatic function * impaired reanl function * endocrine disorder * gastrointestinal disorder * malignancy * alcohol abuse * previous use of insulin * previou use of based incretin therapy * type 1 diabetes.

Keywords: type 2 diabetes sitagliptin nph insulin glp-1
risk factor analysis for developing metabolic syndrome in korean adults

Conditions: Metabolic Syndrome, Atherosclerosis

Summary: in asia, the prevalence of metabolic syndrome have been dramatically increased. therefore, the investigators intend to the collect the blood sample, laboratory, anthropometric, and body composition parameters prospectively to examine the risk factors of metabolic syndrome. furthermore, the investigators will collect the data of carotid imt and branchial ankle pulse wave velocity to clarify the metabolic risk factors of atherosclerosis.


Eligibility criteria:
inclusion criteria: * apparently healthy people who underwent medical routine check up in korea health promotion center. * age \> 20 years exclusion criteria: * history of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) * stage 2 hypertension * severe renal or hepatic disease
esba105 in patients with severe dry eye

Conditions: Eyes Dry Chronic

Summary: the purpose of this study was to evaluate the efficacy of esba105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global visual analog scale (vas) discomfort score.

following run-in, patients qualifying for treatment were randomized 2:1 to receive esba105 (experimental group) or vehicle (control group) for 4 weeks. patients not qualifying for treatment (based on global vas discomfort score), were discontinued from the study.

Eligibility criteria:
inclusion criteria: * ongoing physician diagnosis of dry eye for at least 6 months. * use of artificial tears, gels, lubricants, or re-wetting drops on a regular basis. * experience persistent ocular discomfort. * other protocol-defined inclusion criteria may apply. exclusion criteria: * contact lens wearers. * severe sjogren's syndrome. * history of corneal surgery including refractive surgeries. * intraocular surgery within 6 months of visit 1. * intraocular or periocular injection within 6 months of visit 1. * lid function abnormalities. * use of steroids, tetracycline, doxycycline, etc., within 30 days of visit 1. * any acute infectious or non-infectious ocular condition of the anterior or posterior segments in either eye within 30 days of visit 1. * diseases/conditions of ocular surface associated with clinically significant scarring/destruction of conjunctiva/cornea. * other protocol-defined exclusion criteria may apply.

Keywords: ocular discomfort
saginil in vs. placebo for gynecologic oncology patients affected by vaginitis

Conditions: Vaginitis

Summary: we hypothesise that the use of adelmidrol (saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.


Eligibility criteria:
inclusion criteria: * gynecologic malignancy * current administration of chemotherapy exclusion criteria: * colpectomy * vaginal cancer * vulvar cancer * bacterial vaginitis

Keywords: patients satisfaction side effects
urinary aquaporin 2 and expression of the nphs2 gene in adults suffering from nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: we want to test the hypothesises that patients with nephrotic syndrome have a higher excretion of aqp2 in the urine,that they have a higher concentration of avp,and a lower c-h2o.everything will normalize, when the syndrome is in remission.furthermore we want to test the hypothesis that the expression of mutations in the nphs2-gene,that codes for podocin,will cause a lack off or a poorer response in the treatment of nephrotic syndrome


Eligibility criteria:
inclusion criteria: adult patients with nephrotic syndrome in the years 1995 until now; both male and female; the kidney disease must be based upon a kidney biopsy ; age \> 18 years - exclusion criteria: severe diseases in the heart, lungs or liver; diabetes mellitus; other not well-treated diseases in endocrine organs; cancer unwillingness to participate -

Keywords: aqp-2 nphs2-gene
a study of hs-20094 in healthy participants

Conditions: Type 2 Diabetes

Summary: this study includes two parts (single ascending dose, sad; multiple-ascending dose, mad) and enrolls healthy participants. participants in sad accept single subcutaneous (sc) injection of hs-20094 and participants in mad accept sc injection of hs-20094 once weekly for 4 weeks. the main purpose of this study is to determine 1) the safety of hs-20094; 2) how much hs-20094 gets into the bloodstream and how long it takes the body to get rid of it.3) how hs-20094 affects the levels of blood sugar, insulin and weight.


Eligibility criteria:
inclusion criteria: 1. screening weight of male ≥50 kg, female≥45 kg and 19≤bmi≤28 2. subjects agree to use an effective method of contraception and avoid sperm or egg donation for the duration of the study and for 6 months following the last dose of investigational product 3. agree to avoid alcohol, foods and beverages containing xanthine or caffeine (including chocolate, tea, coffee, cola, etc.) from 48 hours prior to administration to last visit, and to avoid strenuous exercise exclusion criteria: 1. pregnant or lactating women 2. subjects have a medical history of cardiovascular, respiratory, liver, kidney, digestive tract, mental, neurological, hematology or metabolic abnormalities (e.g., repeated hypoglycemia for unknown reasons) and are judged not suitable for this study by the investigator. 3. subjects with abnormal screening vital signs, physical examination, laboratory examination or 12 lead electrocardiogram results with clinical significance 4. have a history of drug allergy, or known allergies to hs-20094, glucagon-like peptide (glp)-1 analogs, or glucose-dependent insulinotropic polypeptide (gip) receptor agonism 5. received systemic steroid therapy, immunomodulator therapy or chemotherapy in the 3 months prior to screening, or are likely to receive these treatments during the study period 6. have a history of digestive disease (e.g., gastroesophageal reflux disease, gallbladder disease, or chronic enteritis) that may affect gastrointestinal adverse events assessment or any other gastrointestinal disease (e.g., gastric bypass surgery, pyloric stenosis, etc.) that may affect gastric emptying 7. have a diet, weight loss treatment or significant lifestyle changes prior to 30 days of administration
the effects of oral probiotics and herbal supplementation on the gut microbiome and sebum excretion rate in non-cystic acne

Conditions: Acne Vulgaris; Acneiform Eruptions; Skin Diseases; Sebaceous Gland Diseases

Summary: the purpose of this study is to evaluates how probiotics and dietary supplementation with an herbal powder can shift the gut microbiome in those with non-cystic acne vulgaris.

the investigators hope to evaluate the effects of oral supplements in changing intestinal health and the gut bacteria in patients with non-cystic acne vulgaris. acne is a chronic inflammatory condition that is estimated to affect greater than 85% of the population at some point. while antibiotics are typically used for systemic therapy, it can increase the risk for drug-resistant bacteria and shift the gut microbiome in a negative way. on the other hand, probiotics and dietary supplementation have been shown to support the gut microbiome. in this study, participants will be randomized to either receiving a probiotic or powder supplement. this means that participants will have an equal chance of receiving either product as half of the participants will be randomized to receive only oral probiotic, and the other half will receive oral supplement powder.

Eligibility criteria:
inclusion criteria: * subjects 12 years of age until 45 years of age * the presence of mild to moderate acne based on investigator global assessment. * presence of at least 10 inflammatory lesions and at least 5 non-inflammatory lesions exclusion criteria: * the presence of severe acne as noted by the investigator global assessment. * those who are unwilling to discontinue oral probiotic-based supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment. * those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide for 2 weeks prior to enrollment * those who are unwilling to keep their facial regimen the same throughout the study * individuals who have been on an oral antibiotic for acne within the previous one month. * individuals who are pregnant or breastfeeding. * individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study. * individuals on oral contraceptive pills or progesterone or estrogen containing therapies * use of isotretinoin within the three months prior to enrollment. * individuals on finasteride or dutasteride * current tobacco smoker or a tobacco smoking history

Keywords: microbiome probiotics dietary supplementation
bol-dp-o-04 in patients with low back pain and sciatica

Conditions: Low Back Pain; Sciatica

Summary: the study is aimed to evaluate the pain-relieving effect of bol-dp-o-04, in addition to soc, on low back pain and sciatica.

a prospective, single-center, double-blind, placebo-controlled trial of bol-dp-o-04 in patients with low back pain and sciatica. the study is aimed to evaluate the pain-relieving effect of bol-dp-o-04, in addition to soc, on low back pain and sciatica.

Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. mild to severe low back pain and/or sciatica 3. imaging studies (ct or mri) supporting anatomical abnormality that could be the cause of the symptoms 4. must be physically and mentally willing and able to comply with the treatment regimen and understand the informed consent and study procedures 5. signed and dated informed consent form (icf) 6. non-responsive to standard therapy for at least 1 month exclusion criteria: 1. vas pain subscale score at screening is less than 6 (with 0 being no pain and 10 being worse imaginable pain) 2. known allergy to cannabis or its components 3. a patient who is pregnant or intends to become pregnant during the study 4. a patient who is nursing or intends to nurse during the study 5. a patient suffering from a mental disorder precluding administration of study drug 6. prisoners 7. a patient is unable to sign an informed consent form 8. unstable angina pectoris 9. cardiac insufficiency precluding cannabis administration 10. immunosuppressed patients unless bol-dp-o-04 administration is deemed safe by the treating physician 11. known aspergillus infection 12. panic attacks or anxiety unless a psychiatrist allowed bol-dp-o-04 following intake interview 13. any mental/psychiatric illness in first-degree relative in a young patient \< 30-year-old. 14. patient with congestive heart failure 15. subjects who get the following medications: opiates, primidone, phenobarbitol, arbamazepine, rifampicin, rifabutin, troglitazone, and hypericum perforatum
role of urinary biomarker neutrophil gelatinase associated lipocalcin (ngal) in early prediction of aki in cirrhosis of liver

Conditions: Renal Failure

Summary: kidney dysfunction is a complex and common event in patients with liver cirrhosis. although novel treatments have shown some promising results , acute kidney injury remains a major complication of decompensated liver cirrhosis with high morbidity and mortality rates . aki occurs in up to 19-20% of hospitalized patients with liver cirrhosis and among the most frequent causes are prerenal azotemia (pra), hepatorenal syndrome and acute tubular necrosis , with prevalence rates estimated around 68%, 25%, and 33%, respectively. the introduction and widespread use of diagnostic criteria of aki in the area of cirrhosis has contributed to an increased awareness and earlier detection of aki. however, some important problems remain. one of the main issues is the differential diagnosis of aki, particularly between acute tubular necrosis (atn) and hepatorenal syndrome (hrs-aki). this is important because treatment is different; renal replacement therapy (rrt) is used for the former, and vasoconstrictors and albumin are used for the latter.

aim of the study: to determine utility of ngal in chronic liver disease patients with acute kidney injury. objective: 1. to compare urine ngal values in hrs and non-hrs group. 2. to determine optimal cutoff of urine ngal for early determination of hrs. plan of investigation: all the following investigations will be done at admission for the patients who satisfy the inclusion criteria routine blood investigations : cbp, lft, pt- inr, rft urine sodium on day 1 urine spot urine protein creatinine ratio cue urine c/s urine ngal serum creatinine will be repeated on day 3.

Eligibility criteria:
inclusion criteria: * cirrhosis diagnosis by combination of clinical, laboratorial, endoscopic and imaging * age over 18 years old * acute kidney injury (defined by ica-aki criteria) * agreement to participate in the study exclusion criteria: * shock/ccf * age less than 18yrs • * underwent renal replacement therapy within the last 6 week prior to evaluation * prior kidney or liver transplantation * confirmed pregnancy * established ckd * congestive cardiac failure * patients who have taken diuretics in the last 48 hours
re104 safety and efficacy study in postpartum depression

Conditions: Postpartum Depression

Summary: the purpose of this study is to determine if treatment with a single dose of re104 for injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (ppd) as compared to active-placebo.


Eligibility criteria:
inclusion criteria: * is ≤15 months postpartum at screening. * meet dsm-5 criteria for postpartum depression (ppd): experiencing a major depressive episode that began at any time starting at the beginning of the second trimester (≥14 weeks) of pregnancy through 4 weeks post delivery. * has a hamilton depression scale (ham-d) total score meeting severity threshold at screening and baseline. * is not using any psychotropic medications or psychotherapy for 30 days prior to screening, or are on an already stable/established regimen of ssris or psychotherapy for 30 days prior to screening. * has ceased breastfeeding at screening. * has a negative pregnancy test at screening and day 0 prior to study drug administration. exclusion criteria: * history or active postpartum psychosis per investigator assessment. * history of treatment-resistant depression within the current postpartum depressive episode. * has a significant risk of suicide. * active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder. * medically significant condition rendering unsuitability for the study . * has received electroconvulsive therapy (ect) or transcranial magnetic stimulation within 90 days prior to screening. * has used psychedelics such as psilocybin, ayahuasca, mescaline, or lsd (with the exception of cannabis) within 12 months prior to screening. * has used or will need to use prohibited medications.
the clinical and prognostic features of pres

Conditions: Posterior Reversible Encephalopathy Syndrome; Pregnancy Outcomes; Preeclampsia; Eclampsia

Summary: the purpose of this study is to determine the features of clinical imaging, disease severity and pregnancy outcomes in posterior reversible encephalopathy syndrome with preeclampsia or eclampsia.

the investigators retrospectively collected data (general information, clinical data, biochemical indicators, imaging features, and pregnancy outcome) from pregnant woman diagnosed with pres with preeclampsia or eclampsia to analyze features of clinical imaging, disease severity and pregnancy outcomes during 2012 to 2021.then, the investigators grouped all the patients into early onset group and late onset pe group according to gestational weeks to analyze differences of clinical imaging. finally, the investigators grouped all the patients into good pregnancy outcomes group and poor pregnancy outcomes group according to diagnostic criteria, including the incidence of stillbirth and premature birth, to analyze differences of clinical imaging .

Eligibility criteria:
inclusion criteria: 1. patients were diagnosed of pres with pe or e 2. all patients provided written informed consent exclusion criteria: 1. patients combined with other neurological disorders 2. patients combined with mental illness